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Abstract
Background: In idiopathic Parkinson’s disease (IPD) transcranial sonography (TCS) represents an alternative
diagnostic method to verify clinical diagnosis. Although the phenomenon of an increased echogenicity of the
Substantia nigra (SN) is well known this method is still not widly used in the diagnostic workup. Until now
reliability of this method is still a matter of debate, partly because data only existed from a few laboratories using
the same ultrasound machine. Therefore our study was conducted to test the reliability of this method by using a
different ultrasound device and examining a large population of control and IPD subjects by two examiners to
calculate interobserver reliability.
Method: In this study echogenicity of SN was examined in 199 IPD patients and 201 control subjects. All
individuals underwent a neurological assessment including Perdue pegboard test and Webster gait test. Using a
Sonos 5500 ultrasound device area of SN was measured, echogenicity of raphe, red nuclei, thalamus, caudate and
lenticular nuclei, width of third and lateral ventricle were documented.
Results: We found a highly characteristic enlargement of the SN echogenic signal in IPD. The cut-off value for the
SN area was established using a ROC curve with a sensitivity of 95% corresponding to an area of SN of 0.2 cm
2
and was found to be equivalent to the cut-off values of other studies using different ultrasound devices.
Conclusions: Our study shows that TCS is a reliable and highly sensitive tool for differentiation of IPD patients
from individuals without CNS disorders.
Background
Diagnosis of idiopathic Parkinson’sd i s e a s e( I P D )i s
usually based on clinical criteria. However, in some
cases differential diagnosis especially in early stages of
the disease might be difficult. Single photon emission
tomography (SPECT) or positron emission tomography
(PET) may pose problems in terms of costs, availability
and exposure to radiation. In recent years, transcranial
B-mode sonography (TCS) appeared as new diagnostic
modality to support the clinical diagnosis of IPD using a
different physical principle of imaging. Since the first
and pathbreaking description of an increased echogeni-
city of the substancia nigra (SN) in IPD by Becker et al
in 1995, these findings were corroborated by several stu-
dies since then [1-9]. However, TCS is not a widespread
diagnostic method, because patient and control cohorts
so far were small and diagnostic thresholds appeared to
be dependent on the technology used. In fact, reference
values in large patient groups so far have been only
established for Siemens Sonoline Elegra (Siemens, Erlan-
gen, Germany) and lately for Aplio (Toshiba Medicals,
Japan) [2,3,8,10]. We used a different ultrasound device,
SONOS 5500, Philips, Netherlands, but followed an
established examination protocol. Until now studies
using the same ultrasound machine only involved small
subject groups. Vlaar et al examined 82 patients with
unclassified Parkinsonian syndromes using a SONOS
5500 and reported a sensitivity of 50% to differentiate
IPD patients from patients without nigrostriatal degen-
eration or atypical Parkinsonian syndromes (specificity
82% and 43% respectively). Remarkably a positive quali-
tative scoring of the SN echogenicity always corre-
sponded to a SN area larger than 0.2 cm
2 [11]. Hagenah
et al reported a sensitivity of 0.71 and a specificity of
0.58 at a cut-off of 0.27 cm
2 SN area examining 58 indi-
viduals, 21 controls, 24 with clinically definite PD and
13 unaffected Parkin gene carriers [12]. In another study
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bers with a PINK1 mutation and 15 relatives of patients
with sporadic PD compared to 18 healthy subjects was
documented [13]. The current study examines the echo-
genicity of the SN in IPD in a very large cohort of
patients and controls. Aim of this study was to clarify
the influence of age or life circumstances on the echo-
genicity of SN in healthy and IPD individuals. A further
aim was to establish reference values beyond the most
o f t e nu s e du l t r a s o u n dt e c h n ology and to provide data
on the interobserver reliability of the method. This
ultrasound technique has often been criticized as subjec-
tive, as observer and device dependent.
Methods
The group of IPD patients consisted of 199 individuals
(131 males and 68 females). Diagnosis was established
according to the United Kingdom brain bank criteria
[14]. Participants were consecutive patients recruited
from the Parkinson clinic Bad Nauheim and from the
University hospital Giessen. The control group consisted
of 201 individuals (89 males, 112 females) with no
known central nervous disease (NCD). 140 of them
were either university students or clinic staff members,
61 were patients with peripheral nerve disorders or
musculosceletal diseases or visitors. Controls were cho-
sen, so that at least 30 individuals per decade from age
20 to 79 could be examined. All participants gave writ-
ten informed consent according to the Declaration of
Helsinki. The study was approved by the ethics commit-
tee of the University clinic Giessen, Germany. All indivi-
duals were seen by an experienced neurologist (SM, IR)
and underwent a thorough neurologic examination
including Unified Parkinson’s Disease Rating Scale
(UPDRS) part I-IV, Webster’s gait test [15,16]. Purdue’s
pegboard test was performed in all subjects to quantify
hand motor function [17]. The medical and social his-
tory was taken from all individuals including date and
area of birth, exposure to toxicologic substances (wood
preservatives, solvents, pesticides), nutrition (regular
continental, vegeterian, protein-rich), diseases, medica-
tion, use of alcohol or nicotin. For IPD patients onset
and duration of disease, start, preparation and dose of
medication as well as side effects such as dyskinesia
were documented. A Levodopa Equivalent Dose (LED)
was estimated [18-20]. For TCS examination a color-
coded phased array ultrasound system equipped with a
1,8-3,6 MHz transducer was used (Sonos 5500, Philips,
Netherlands). The examination was performed through
the left and right temporal acoustic bone window with a
penetration dephth of 16 cm, a dynamic range of 50 dB,
and a mechanical index of 1,6. The image brightness
was adapted as needed using B-mode gain and lateral
gain control. The mesencephalic brainstem was
identified by its butterfly shape (figure 1), after image
freezing the structure was zoomed two-fold. Within this
structure the hyperechogenic signal of the ipsilateral SN
was identified. A structure is classified as hyperecho-
genic if the intensity of the ultrasound signal is abnor-
mally increased compared with a reference structure
usually the surrounding white matter. The measurement
was carried out after optimisation of the signal at its lar-
gest extension. The area of the echogenic SN was sur-
rounded manually with the cursor, the area was
calculated automatically. (for examples see figure 2, 3)
Median Raphe and ipsilateral red nuclei were identified.
In the diencephalic insonation plane the contralateral
thalamus was depicted and the width of the third ventri-
cle and the contralateral frontal horn of the lateral ven-
tricle was measured perpendicular at maximal width.
The contralateral thalamic, caudate and lentiforme
nuclei were classified. The ultrasound examination and
measurements were performed according to an interna-
tional consensus [21]. The whole measurement of SN
was repeated by two independent investigators, blinded
to the results of each other- one of them an experienced
sonographer (SM, ES) and the other a well trained stu-
dent (PM, KS). The investigators were not blinded to
the subjects while scanning but not explicitly informed
about the group the subject belonged to.
Statistics
Descriptive statistics are given as median and lower
(25
th percentile) and upper (75
th percentile) quartile.
Correlation analysis was performed by Spearman’sr a n k
correlation. For group comparison an unpaired non-
parametric data Mann- Whitney-test and for non-para-
metric data Kruskal-Wallis Test was used. A correction
for multiple comparisons was performed where appro-
priate. For comparison between IPD and NCD group
the combined measurements of left and right side were
used. The cut-off value was established by Receiver
Operating Characteristics (ROC) analysis. Interobserver
reliability was calculated as mean ± SD and variation
coefficient was estimated.
Results
In the IPD group transcranial ultrasound could be per-
formed in 183 individuals. 183 of 199 patients (92%)
had a sufficient acoustic bone window at least on one
side and 15 of these patients only on one side. Their
median age was 66 (62;71) years, 24 had a predominant
tremor form, 80 akinetic-rigid form and 79 equivalent
form. In the NCD group examination was possible uni-
laterally in all individuals, whereas, bilateral investigation
was not possible in 6 of 201 individuals (3%). The med-
ian age of NCD individuals was 49 (32;64) years.
In the IPD group median area of the SN was 0.3 cm
2
(0.25;0.37) on the left side and 0.29 cm
2 (0.25;0.36) on
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left side was 0.12 cm
2 (0.1;0.15), on the right side 0.12
cm
2 (0.09;0.15). The difference of SN sizes between IPD
patients and NCD healthy individuals proofed to be
highly significant (p < 0.001).
The measurement of SN was found to be adequately
reproducible considering the small size of the structure;
variation between two observers was small (variation
coefficient 0.085). The difference was 0.018 cm
2 ±0 . 0 1 5
cm
2, the range 0.0 cm
2 to 0.12 cm
2. Evaluation concern-
ing group membership applying the cut-off of 0,2 cm
2
differed only in 2 NCD and 3 IPD subjects.
The cut-off value for the SN area was established using a
Receiver Operating Characteristics (ROC) curve with a
sensitivity (true positive rate) of 95%. This corresponded
to an area of SN of 0.2 cm
2 (AUC 0.989). At this cut-off
value specificity in our cohort was 96%.
In the NCD group only 8 of 201 individuals (4%) showed
a SN area bilaterally >0,2 cm
2. An unilateral SN size >0,2
cm
2 was found in 13 of 201 individuals (6.5%). (see table 1)
In NCD group SN size increased with age (Spearman
Rho = 0.17, p < 0.02), but individuals with SN size >0,2
cm
2 did not significantly differ in age from individuals
with SN size <0,2 cm
2 (Mann-Whitney-U p > 0.5). In
NCD group individuals SN size was larger with decreas-
ing hand motor function measured in Pegboard test
(Spearman Rho -0.23, p = 0.01), but no significant dif-
ference of motor function was found between healthy
subjects with normal or increased SN size (Mann-Whit-
ney-U p > 0.1). No correlation was found with Web-
ster’s gait test (Spearman Rho 0.13, p > 0.08).
In the IPD patient group only 4.9% (9 of 183 patients)
showed a unilateral SN area <= 0,2 cm
2 and 3.6% (6 of
168 patients) bilaterally. (see table 2) No significant cor-
relation of SN echogenicity with age (Spearman Rho
0.02, p > 0.7), sex, country of origin, education, contact
to toxins, nutrition or concomitant diseases was
observed neither in the IPD nor the NCD group. In IPD
subjects no differences of SN echogenicity were found
between different clinical subtypes (Kruskal-Wallis, Chi
2
Figure 1 TCS image of mesencephalon of healthy individual. In the center the hypoechogenic mesencephalon (arrow) with small
hyperechogenic SN is shown. Contralateral skull (^^^).
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p > 0.5) nor with presentation of fluctuations (Kruskal-
Wallis, Chi
2 = 0.01, p > 0.9), hyperkinesia (Kruskal-
Wallis, Chi
2 = 0.05, p > 0.8) or LED (Spearman Rho
0.06, p > 0.4) or start of dopaminergic medication
(Spearman Rho 0.01, p > 0.9) (see table 3). SN sizes did
not correlate with the clinically more affected body side
(Kruskal-Wallis, Chi
2 =0 . 2 ,p>0 . 3 )n o rw i t hh a n d e d -
ness (Kruskal-Wallis, Chi
2 = 1.6, p > 0.2) or Pegboard
results (Kruskall-Wallis, Chi
2 = 1.3, p > 0.5). No correla-
tion between Hoehn&Yahr stages of disease and SN size
was found (Spearman Rho 0.06, p = 0.45). Even though
IPD patients with SN>0.2 cm
2 had worse results in the
Pegboard tests (Mann-Whitney-U p = 0.03), they did
not differ in UPDRS (Mann-Whitney-U p = 0.3) or
Webster’sg a i tt e s t( M a n n - W h i t n e y - Up=0 . 3 7 )f r o m
test negative (SN <= 0,2 cm
2) IPD patients.
Median width of third ventricle in the IPD group was
0.56 cm (0.42;0.73), in the NCD group 0.31 cm
(0.22;0.48). The width of the frontal horn of the lateral
ventricle was 1.46 cm (1.27;1.69) in IPD on the right side
and 1.46 cm on the left side (1.24;1.71). In the NCD
group it was 1.15 cm (1.02;1.35) on the right and 1.17 cm
(1.02;1.37) on left side. As expected the size of the third
and lateral ventricle increased with age in both groups
(NCD: Spearman Rho 0.74, p < 0.01; IPD: Spearman Rho
0.42, p < 0.01). Classification of raphe or red nuclei, tha-
lamus, lentiform and caudate nuclei did not differ signifi-
cantly between NCD and IPD group. (see table 4)
Discussion
Transcranial sonography is a valuable method for differ-
entiation of IPD patients from healthy individuals. We
could demonstrate a highly characteristic enlargement
of SN echogenic signal in patients with IPD. Our results
correspond to the findings of other studies. Due to the
large group of patients and control subjects studied our
results emphasize the importance of this diagnostic tool.
The SN echogenic sizes found in our large and homoge-
neous cohort of individuals without CNS disorder ran-
ging in age from 20 to 79 years correspond to the
results in smaller studies reporting a median SN sizes of
0.14 cm
2 for healthy subjects aged 50 to 59 years, 0.10
Figure 2 TCS image (zoom) of butterfly shaped mesencephalic
brainstem of healthy individual, left SN (arrow) with an area of
0.10 cm
2.
Figure 3 TCS image (zoom) of mesencephalic brainstem of
patient with IPD, left SN (arrow) with an area of 0.43 cm
2.
Table 1 Clinical and TCS data of NCD group
Age, years Number of NCD individuals SN, cm
2* Prevalence of SN >0,2 cm
2,N ;i n%
20-29 35 0.11 (0.06;0.13) 2; 5.7
30-39 34 0.13 (0.07; 0.15) 1; 2.9
40-49 32 0.11 (0.06; 0.13) 1; 3.1
50-59 36 0.13 (0.07; 0.16) 2; 5.6
60-69 31 0.13 (0.07; 0.16) 0; 0
70-80 33 0.14 (0.05; 0.15) 2; 6.1
*Data are given as median with lower and upper quartile (25th and 75th percentile respectively).
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2 for subjects 60 to 69 years, and 0.15 cm
2 for sub-
jects 70 to 79 years and median SN sizes for patients
with nonparkinsonian cerebral disorders of 0.13 cm
2,
although different ultrasound equipment was used [2,8].
Our IPD patients showed a median SN echogenic size
of 0.29 cm
2. This is slightly higher than the reported
median SN echogenic size of IPD patients of 0.25 cm
2
using Siemens ultrasound devices [2,8].
We set our cut-off value at a sensitivity of 95%. Inter-
estingly, our cut-off value turned out to be equivalent to
the cut-off values of other studies, despite differences in
the median values using different ultrasound equipment
[2,8]. It has to be admitted that in the study of Hagenah
et al using the same device SONOS 5500 a lower sensi-
tivity and specificity at a differing cut off of 0,27 cm
2
was reported, probably due to the small sample size or
due to the different patient sample (Parkin mutation
carriers) [12]. Unfortunately formal studies comparing
different devices in the same cohort are still lacking.
Nevertheless based on our results and considering that
in other studies using the same or different ultrasound
devices similar scoring criteria concerning SN area were
established, the hypothesis that the sonographic method
is not substantially influenced by the ultrasound device
seems acceptable [11,2,8]. The validity of the scoring cri-
teria, independent of the devices used, is of paramount
importance, since this is the basis to advocate TCS as
the method of choice in the diagnostic workup of move-
ment disorders.
The dependence of this ultrasound technique on
experience and a relative subjectivity of results is an
often discussed matter of critique. Regarding the low
interobserver variance in our study these arguments
might be softend. As documented through our data a
good reproducibility can be achieved. Our study design
did not allow a blinding towards group membership of
individuals included in this study and this may have
influenced the results of the study. Given the clinical
aspect of IPD patients a sufficient blinding of experi-
enced examiners is almost impossible or would at least
require an enormous effort as reported by Prestel et al.
[16] We have to admit that our results might be influ-
enced by the age difference of the groups and the lack
of a sufficient blinding, so the specificity might be
slightly overestimated.
In our study we found a rate of 6.5% of NCD indivi-
duals with at least unilaterally increased SN size. A simi-
lar rate of about 9% has been reported before [1,2].
Despite the frequency of increased SN size in NCD in
our study is higher than the estimated risk of about 0.1%
of IPD in the general population it is thought to reflect a
vulnerability for developing nigrostriatal disorders [2].
A slight increase of SN size revealed with increasing age
and we found worse hand motor function (Pegboard test)
Table 2 Clinical and TCS data of IPD group
Age, year Number of IPD individuals SN, cm
2* Prevalence of SN <= 0,2 cm
2,N ;i n%
40-49 8 0.28 (0.24; 0.39) 0; 0
50-59 27 0.31 (0.28; 0.33) 1; 0
60-69 90 0.30 (0.26; 0.36) 6; 6.7
70-85 58 0.29 (0.25; 0.38) 3; 5.2
*Data are given as median with lower and upper quartile (25th and 75th percentile respectively).
Table 3 Clinical data of IPD patients grouped according to SN size in TCS
Data Whole IPD group* (n =
183)
IPD patients SN <= 0.2 cm
2*
(n = 9)





Age, y 66 (62;71) 69 (67;75) 66 (62;71) 0.18
Age at disease onset, y 61 (54;66) 67 (59;74) 60 (54;66) 0.13
Disease duration,
months
78 (48;120) 60 (36;96) 81 (48;120) 0.23
Duration since L-Dopa
start, y
5 (3; 8) 3 (1,5;2,2) 5 (3;8) 0.37
L-Dopa equivalent dose,
mg
560 (310;679) 519 (306;628) 558 (310;679) 0.83
Hoehn&Yahr score 2.5 (2.5;3) 2.5 (2.5;2.5) 2.5 (2.5;3) 0.88
UPDRS III score
26 (17;34)
27 (20;31) 25 (17;34) 0.28
Pegboard test score 16 (12;20) 13 (13;14) 16 (12;20) 0.03
Webster gait test 13 (10;15) 13 (13;18) 12 (11;15) 0.37
*Data are given as median with lower and upper quartile (25th and 75th percentile respectively). y (years)
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demonstrated that elderly subjects without prediagnosed
extrapyramidal disorder but with increased SN size devel-
oped more often signs of motor retardation [3].
Previous studies showed no change of SN sizes in the
course of the disease and according to our results no
correlation with parameters of disease severity i.e.
Hoehn & Yahr stages, UPDRS, Webster-, Pegboard-
Test. It is assumed that SN hyperechogenicity reflects
an increased amount of iron in the SN, bound to pro-
teins other than ferritin [1,2,9]. It is regarded as a trait
marker pointing to a predisposition for the disease not a
severitiy marker reflecting proceeding nigral cell loss
[21]. Our results show that neither sonographic classifi-
cation of raphe, thalamus, lenticular or caudate nuclei
nor measurement of ventricles could serve as suitable
parameters to discriminate healthy individuals from IPD
patients. Recent studies showed that these parameters
are of paramount importance to distinguish atypical Par-
kinsonian syndromes from IPD [22].
Conclusion
Our study shows that TCS is a reliable and highly sensi-
tive tool for differentiation of IPD patients from indivi-
duals without CNS disorders. In consideration of other
studies our results point to a relative independence of
the SN scoring parameters on the ultrasound
equipment.
Our study focused on clinicaly diagnosed IPD and did
not include atypical Parkinsonian syndromes, this may be
seen as a shortcoming. A possible bias influencing our
results might be the age difference of the two groups
though the investigators were not sufficiently blinded.
Acknowledgements
We thank all patients and healthy volunteers for consenting to take part in
this study and Dr. M. Oechsner for his contribution in the recruitment of
patients.
Authors’ contributions
SM, ES, KS, PM carried out the sonography, SM, IR, KS, PM made substantial
contribution to the design of the study, contributed to the patient data
acquisition and neurologic examinations. SM drafted the manuscript. ES, IR,
MK helped in drafting and revision of the manuscript. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 5 August 2009
Accepted: 21 January 2010 Published: 21 January 2010
References
1. Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K: Degeneration of
substantia nigra in chronic Parkinson’s disease visualized by transcranial
color-coded real-time sonography. Neurology 1995, 45:182-184.
2. Berg D, Becker G, Zeiler B, Tucha O, Hofmann E, Preier M, Benz P, Jost W,
Reiners K, Lange KW: Vulnerability of the nigrostriatal system as detected
by transcranial ultrasound. Neurology 1999, 53:1026-1031.
3. Berg D, Siefker C, Ruprecht-Dorfler P, Becker G: Relationship of substantia
nigra echogenicity and motor function in elderly subjects. Neurology
2001, 56:13-17.
4. Berg D, Roggendorf W, Schroder U, et al: Echogenicity of the substantia
nigra: association with increased iron content and marker for
susceptibility to nigrostriatal injury. Arch Neurol 2002, 56:999-1005.
5. Jabs BE, Berg D, Merschdorf U, Bartsch AJ, Pfuhlmann B: Differences in
substantia nigra echogenicity of nosological subtypes within the
schizophrenic spectrum. A preliminary transcranial ultrasound study.
Neuropsychobiology 2001, 44(4):183-186.
6. Postert T, Lack B, Kuhn W, et al: Basal ganglia alterations and brain
atrophy in Huntington’s disease depicted by transcranial real time
sonography. J Neurol Neurosurg Psychiatry 1999, 67:457-462.
7. Ruprecht-Dörfler P, Berg D, Tucha O, Benz P, Meier-Meitinger M, Alders GL,
Lange KW, Becker G: Echogenicity of the substantia nigra in relatives of
patients with sporadic Parkinson’s disease. Neuroimage 2003,
18(2):416-422.
8. Walter U, Wittstock M, Benecke R, Dressler D: Substantia nigra
echogenicity is normal in non-extrapyramidal cerebral disorders but
increased in Parkinson’s disease. J Neural Transm 2002, 109:191-196.
Table 4 Qualitative assessment of echogenicity of brainstem raphe, red nucleus, thalamus, caudate and lenticular
nuclei in NCD and IPD group
Structure NCD group (n = 201) IPD group (n = 183)
Brainstem raphe grade 1:n = 23
grade 2:n = 176
grade 1:n = 30
grade 2:n = 130
right left right left
Red nucleus grade 1:n = 44
grade 2:n = 150
grade 1:n = 44
grade 2:n = 154
grade 1:n = 47
grade 2:n = 113
grade 1:n = 49
grade 2:n = 109
Thalamus grade 1:n = 198
grade 2,3:n = 0
grade 1:n = 198
grade 2,3:n = 0
grade 1:n = 157
grade 2,3:n = 0
grade 1:n = 156
grade 2:n = 1
grade 3:n = 0
Lenticular nucleus grade 1:n = 194
grade 2:n = 3
grade 1:n = 194
grade 2:n = 4
grade 1:n = 155
grade 2:n = 13
grade 3:n = 1
grade 1:n = 150
grade 2:n = 19
grade 3:n = 3
Caudate nucleus grade 1:n = 197
grade 2,3:n = 1
grade 1:n = 196
grade 2:n = 2
grade 3:n = 0
grade 1:n = 162
grade 2:n = 3
grade 3:n = 2
grade 1:n = 166
grade 2:n = 4
grade 3:n = 0
Mann-Whitney-U-Test showed no significance between NCD and IPD group for echogenicity of all structures. Structure echogenicity was classified: Raphe:
markedly echogenic (2); interrupted or not visible (1). Red nucleus: weakly echogenic (1), markedly echogenic (2), hyperechogenic (3). Thalamus, caudate and
lenticular nucleus: iso- or hypoechogenic (1), hyperechogenic (2), markedly hyperechogenic (3).
Mehnert et al. BMC Neurology 2010, 10:9
http://www.biomedcentral.com/1471-2377/10/9
Page 6 of 79. Walter U, Niehaus L, Probst T, Benecke R, Meyer BU, Dressler D: Brain
parenchyma sonography discriminates Parkinson’s disease and atypical
parkinsonian syndromes. Neurology 2003, 60(1):74-77.
10. Okawa M, Miwa H, Kajimoto Y, Hama K, Morita S, Nakanishi I, Kondo T:
Transcranial sonography of substantia nigra in Japanese patients with
Parkinson’s disease or atypical Parkinsonism: clinical potential and
limitations. Intern Med 2007, 46(18):1527-31.
11. Vlaar AM, de Nijs T, van Kroonenburgh MJ, Mess WH, Winogrodzka A,
Tromp SC, Weber WE: The predictive value of transcranial duplex
sonography for the clinical diagnosis in undiagnosed parkinsonian
syndromes: comparison with SPECT scans. BMC Neurol 2008, 8:42.
12. Hagenah J M, König I R, Becker B, Hilker R, Kasten M, Hedrich K,
Pramstaller P P, Klein C, Seidel G: Substantia nigra hyperechogenicity
correlates with clinical status and number of Parkin mutated alleles. J
Neurol 2007, 254:1407-1413.
13. Hagenah J M, Becker B, Bruggemann N, Djarmati A, Lohmann K,
Sprenger A, Klein C, Seidel G: Transcranial sonography findings in a large
family with homozygous and heterozygous PINK1 mutations. J Neurol
Neurosurg Psychiatry 2008, 79:1071-1074.
14. Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of
idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases.
J Neurol Neurosurg Psychiatry 1992, 55(3):181-184.
15. Fahn S, Elton RL, Members of the UPDRS Development Committee: The
Unified Parkinson’s Disease Rating Scale. Recent developments in
Parkinson’s disease Florham Park, NJ: Macmillan Health Care InformationFahn
S, Marsden CD, Calne DB, Goldstein M 1987, 2:153-163, 293-304..
16. Webster DD: Critical analysis of the disability in Parkinson’s disease. Mod
Treat 1968, 5:257-282.
17. Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ: Which clinical sign of
Parkinson’s disease best refelcts the nigrostriatal lesion?. Ann Neurol
1997, 41(1):58-64.
18. Maschke M, Gomez CM, Tuite PJ, et al: Dysfunction of the basal ganglia,
but not the cerebellum, impairs kinaesthesia. Brain 2003, 126:2312-22.
19. Hobson DE, Lang AE, Martin WR, et al: Excessive daytime sleepiness ans
sudden onset sleep in Parkinson disease: a survey by the Canadian
Movement Disorders Group. JAMA 2002, 287:455-63.
20. Parkin SG, Gregory RP, Scott R, et al: Unilateral and bilateral palidotomy
for idiopathic Parkinson’s disease: a case series of 115 paients. Mov
Disord 2002, 17:682-92.
21. Walter U, Behnke S, Eyding J, Niehaus L, Postert T, Seidel G, Berg D:
Transcranial brain parenchyma sonography in movement disorders:
state of the art. Ultrasound Med Biol 2007, 33(1):15-25.
22. Prestel J, Schweitzer KJ, Hofer A, Gasser T, Berg D: Predictive value of
transcranial sonography in the diagnosis of Parkinson’s disease. Mov Dis
2006, 21(10):1763-1765.
Pre-publication history
The pre-publication history for this paper can be accessed here:http://www.
biomedcentral.com/1471-2377/10/9/prepub
doi:10.1186/1471-2377-10-9
Cite this article as: Mehnert et al.: Transcranial sonography for diagnosis
of Parkinson’s disease. BMC Neurology 2010 10:9.
Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Mehnert et al. BMC Neurology 2010, 10:9
http://www.biomedcentral.com/1471-2377/10/9
Page 7 of 7